spacer
spacer

PDBsum entry 4ggq

Go to PDB code: 
Top Page protein ligands metals Protein-protein interface(s) links
Isomerase, protein binding PDB id
4ggq
Jmol
Contents
Protein chains
191 a.a.
177 a.a.
Ligands
861 ×4
PEG
Metals
_CA ×2
Waters ×424

References listed in PDB file
Key reference
Title A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins.
Authors D.W.Begley, D.Fox, D.Jenner, C.Juli, P.G.Pierce, J.Abendroth, M.Muruthi, K.Safford, V.Anderson, K.Atkins, S.R.Barnes, S.O.Moen, A.C.Raymond, R.Stacy, P.J.Myler, B.L.Staker, N.J.Harmer, I.H.Norville, U.Holzgrabe, M.Sarkar-Tyson, T.E.Edwards, D.D.Lorimer.
Ref. Antimicrob Agents Chemother, 2014, 58, 1458-1467. [DOI no: 10.1128/AAC.01875-13]
PubMed id 24366729
Abstract
Macrophage infectivity potentiators (Mips) are immunophilin proteins and essential virulence factors for a range of pathogenic organisms. We applied a structural biology approach to characterize a Mip from Burkholderia pseudomallei (BpML1), the causative agent of melioidosis. Crystal structure and nuclear magnetic resonance analyses of BpML1 in complex with known macrocyclics and other derivatives led to the identification of a key chemical scaffold. This scaffold possesses inhibitory potency for BpML1 without the immunosuppressive components of related macrocyclic agents. Biophysical characterization of a compound series with this scaffold allowed binding site specificity in solution and potency determinations for rank ordering the set. The best compounds in this series possessed a low-micromolar affinity for BpML1, bound at the site of enzymatic activity, and inhibited a panel of homologous Mip proteins from other pathogenic bacteria, without demonstrating toxicity in human macrophages. Importantly, the in vitro activity of BpML1 was reduced by these compounds, leading to decreased macrophage infectivity and intracellular growth of Burkholderia pseudomallei. These compounds offer the potential for activity against a new class of antimicrobial targets and present the utility of a structure-based approach for novel antimicrobial drug discovery.
PROCHECK
Go to PROCHECK summary
 Headers